Products:

Xenazine®

XENAZINE®: 25 mg, scored tablets
(INN: tetrabenazine)

Xenazine® is indicated for the treatment of movement disorders associated with Huntington’s chorea and hemiballismus.

Xenazine® was developed by Cambridge Laboratories (UK). EUSA holds an exclusive agreement for the distribution of Xenazine® in France where it obtained a marketing authorization in France in July 2005.

For information on our products, where they are available and prescribing information, please see the Product Summary table.